Preventing nausea from cancer treatment with new medications
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tests two medications (fosrolapitant and palonosetron) to prevent severe nausea and vomiting in patients with esophageal or lung cancer who are receiving chemotherapy combined with immunotherapy. If the medications work well, they could help patients feel better during treatment and complete their cancer care more comfortably.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal cancer or lung cancer that is advanced or has spread, confirmed by biopsy or cell test
- You have never received chemotherapy before for your cancer
- You are planning to receive at least 4 cycles of chemotherapy combined with immunotherapy
- Your overall health is good enough for treatment (ECOG score 0–1, meaning you can do most normal activities)
- Your blood counts, liver, kidney, and heart function are normal or near-normal
- You are not pregnant, not breastfeeding, and willing to use birth control for 6 months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two anti-nausea medications, rolapitant and palonosetron, to see how well they prevent nausea and vomiting caused by chemoradiotherapy for lung cancer. It aims to help patients feel more comfortable during treatment.
This study tests if two medicines given together, fosaprepitant and palonosetron, can prevent nausea and vomiting caused by strong chemotherapy given over several days. It's for people who have never had chemo before and are about to start a multi-day treatment for a solid tumor.
This trial studies whether palonosetron helps prevent nausea and vomiting caused by chemotherapy that has a moderate risk of vomiting. It may help you feel more comfortable during chemo and avoid treatment interruptions from severe nausea.
This trial tests whether a combination of two anti-nausea drugs (fosrolapitant and palonosetron) can better prevent nausea and vomiting caused by Trastuzumab Rezetecan. If you are starting this cancer treatment, you may be able to join.
This trial tests two medications, fosrolapitant and palonosetron, to see if they can prevent nausea and vomiting caused by a type of cancer treatment called antibody-drug conjugates (ADCs). If you are about to start your first ADC treatment, this study might help you feel better during treatment.
This study tests whether the medication NEPA (Netupitant and Palonosetron) can prevent nausea and vomiting in people who have had surgery for liver, gallbladder, or pancreatic cancer. It may help those who want to avoid post-surgery sickness.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.